Hematologic Malignancy
Diffuse Large B-Cell Lymphoma
CI-CAN-00005107DLBCLExplore in graph →
Hematologic355 active trials5 approved drugs19 evidence items
- NCIt
- C8851
- DOID
- 0050745
- Other
- 4 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005107DLBCLExplore in graph →
Clinical trials
1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06832228 | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL | unknown | N/A | 30 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06530511 | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | unknown | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 4, 2025 |
| clinicaltrials |
| NCT06149169 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | unknown | Phase 2 | 10 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)(COALITION) | unknown | Phase 1 / Phase 2 | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06161896 | Characterization and Clinical Impact of the Gut Microbiota in Lymphoma | unknown | — | 200 | Lars Møller PedersenOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 50 | Li ZhimingOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06424379 | BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.(BCL6-RINHL) | unknown | — | 135 | Hospices Civils de LyonOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT05189197 | A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06412068 | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT03213977 | R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL | unknown | Phase 3 | 475 | Fujian Medical UniversityOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06290817 | Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI | unknown | Phase 2 | 62 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03650933 | A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients | unknown | Phase 3 | 360 | Nanjing Yoko Biomedical Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05875428 | Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05234684 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma(BELIEVE-01) | unknown | Phase 3 | 150 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06186986 | CD30 Imaging in Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 20 | University Medical Center GroningenOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT05577364 | Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | unknown | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT04089215 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | unknown | Phase 2 | 82 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04870853 | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy | unknown | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03121456 | 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma(LYMPHODTECT) | unknown | N/A | 74 | Centre Antoine LacassagneOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05290090 | ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | unknown | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05673447 | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | unknown | Early Phase 1 | 12 | Changhai HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05990985 | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | unknown | N/A | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05974085 | XPO-1 in Combination With RCHOP for DH/TH Lymphoma | unknown | Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05871684 | A Combination Study of CAR-T Therapy in r/r B-NHL | unknown | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05887726 | Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors | unknown | Phase 2 | 30 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05940051 | Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 35 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05940064 | Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05715606 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05834426 | Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers | unknown | — | 50 | Sociedad de Lucha Contra el Cáncer del EcuadorOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05907447 | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types | unknown | — | 10,000 | Ruijin HospitalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05883709 | A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL | unknown | — | 15 | Zhao WeiliOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05874778 | A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission | unknown | Phase 2 | 108 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 25, 2023 | clinicaltrials |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | unknown | Phase 3 | 280 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05863845 | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | unknown | N/A | 52 | Ruijin HospitalOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT05852028 | A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma | unknown | — | 250 | Ruijin HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05816746 | Decitabine and Anti-PD-1 in R/R DLBCL | unknown | Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05823701 | Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | unknown | Phase 2 | 23 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05809180 | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | unknown | N/A | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05786989 | Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 32 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05784987 | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05351346 | Genotype-guided Treatment in DLBCL | unknown | Phase 3 | 1,100 | Ruijin HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05777369 | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT03797170 | Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma | unknown | — | 50 | University of BolognaOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04381741 | CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma(CICPD) | unknown | Phase 1 | 24 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05498259 | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | unknown | Phase 2 | 46 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT05690191 | Chidamide in Patients With Recurrent and Refractory Diffuse Large b | unknown | — | 169 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 18, 2025source: clinicaltrials